Picture loading failed.

Anti-IL17A therapeutic antibody (Pre-made Ixekizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ixekizumab, sold under the brand name Taltz, is an injectable medication for the treatment of autoimmune diseases. Chemically, it is a form of a humanized monoclonal antibody. The substance acts by binding interleukin 17A and neutralizing it, reducing inflammation.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-286-1mg 1mg 3090
GMP-Bios-ab-286-10mg 10mg 21890
GMP-Bios-ab-286-100mg 100mg 148000
GMP-Bios-ab-286-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IL17A therapeutic antibody (Pre-made Ixekizumab biosimilar,Whole mAb)
INN Name Ixekizumab
TargetIL17A
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure6nov:AB
99% SI Structure6nou:AA
95-98% SI StructureNone
Year Proposed2011
Year Recommended2012
CompaniesEli Lilly;Oregon Health & Science University;Torii Pharmaceutical
Conditions ApprovedErythrodermic psoriasis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis
Conditions ActiveAnkylosing spondylitis;Spondylarthritis;Bullous pemphigoid;Pityriasis rubra pilaris;Pyoderma gangrenosum;Rheumatoid arthritis
Conditions Discontinuedna
Development Techna